The International Myeloma Working Group (IMWG) has published dozens of research studies and treatment guidelines on multiple myeloma and its related disorders. The following are a sample of the International Myeloma Working Group’s ranging publication topics:

  • Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma
  • Gene signature combinations improve prognostic stratification of multiple myeloma patients
  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
  • Combining Fluorescent In Situ Hybridization (iFISH) data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group (IMWG) collaborative project

From doctors to patients, the goal of these publications is to help anyone better understand aspects of myeloma. The information provided in the International Myeloma Working Group’s publications seeks to help guide patients and their doctors to treating myeloma in the most effective way for every individual case.




Recommendations developed by the IMWG for diagnosis and management of myeloma were published online in the Journal of Clinical Oncology on March 14, 2016.





This IMWG manuscript provides recommendations on the management of relapsed and refractory myeloma and both autologous and allogeneic transplant.





The IMWG combined the International Staging System with chromosomal abnormalities detected by FISH to evaluate their prognostic value in NDMM.





The IMWG published a study on the assessment of survival and toxicities in elderly myeloma patients, in order to provide suitable therapy recommendations.





The IMWG updates the definition of multiple myeloma to include validated biomarkers along with existing CRAB features.


Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.